1. Market Research
  2. > Healthcare Market Trends
Methicillin-resistant Staphylococcus Aureus  Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • March 2018
  • 177 pages
  • ID: 5371642
  • Format: PDF
  • By Transparency Market Research

Summary

Table of Contents

Global MRSA Drugs Market: Overview
This report on the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market analyzes the current and future scenario of the global market.Rise in private and public funding for R&D of novel anti-MRSA drug molecules, increase in prevalence of MRSA infections, and their improved screening are boosting the growth of the global MRSA drugs market.

According to CDC, two in every 100 people carry MRSA. Introduction of generic drugs for the MRSA treatment, and upsurge in the consumption of antibiotics in the developing countries are some of the factors expected to drive the growth of global MRSA drugs market during the forecast period.

The MRSA drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments.It also provides information and data analysis of the global market with respect to the segments based on drug class, route of administration, distribution channel, and geography.

A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section.Additionally, the report comprises epidemiological assessment of MRSA infection, in terms of causes, complications, current & future treatment options for MRSA, along with its prevalence rate in key countries.

The report contains comparative analysis of key companies operating in the global MRSA drugs market, in terms of strategic developments, current and future market positioning, and their key differential parameters, to help understand the competitive landscape in the market.Moreover, the global corporate scenario is provided in the report with major pipeline products of emerging and established pharmaceutical manufacturers, and their respective dosage forms.

This report also provides market attractiveness and its analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global MRSA drugs market.

Global MRSA Drugs Market: Key Segments
Based on the drug class, the global MRSA drugs market is segmented into lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonist, and others.Lipopeptide accounted for highest market share in 2016, owing to the diversified distribution of daptomycin (lipopeptide) across the globe by key distributors in 2016.

Others drug class is projected to expand at relatively significant CAGR during 2017-2025, which is attributable to the rising incidence of community-acquired MRSA infection.Different types of route of administration in the MRSA drugs market are oral and parenteral.

Parenteral segment dominated the market in terms of market share in 2016, and is expected to continue to lead the global market during forecast period.However, oral segment is likely to expand during 2017-2025, due to presence of numerous oral vaccines against MRSA infection in the developmental phase by key companies.

Various distribution channels in the global MRSA market are hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy held maximum market share in 2016, and is expected to remain dominant by 2025 in terms of revenue. However, online pharmacy is likely to expand with maximum CAGR owing to the rising adoption of the population for digital platform. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global MRSA Drugs Market: Regional Outlook
Geographically, the global MRSA drugs has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report
The report also profiles major players in the global MRSA drugs based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc.

The Global MRSA drugs Market has been segmented as given below:

Global MRSA Drugs Market, by Drug Class
Lipopeptide
Oxazolidinone
Tetracycline
Cephalosporin
Lipoglycopeptide
Folate Antagonist
Others

Global MRSA Drugs Market, by Route of Administration
Oral
Parenteral

Global MRSA Drugs Market, by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global MRSA drugs Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off

($5795)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019" provides an ...

Anthrax - Pipeline Review, H2 2019

Anthrax - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Anthrax - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2019, provides an overview of the Anthrax (Infectious Disease) pipeline ...

Hepatitis Test Kits - Medical Devices Pipeline Assessment, 2019

Hepatitis Test Kits - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Hepatitis Test Kits - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Hepatitis Test Kits - Medical Devices Pipeline Assessment, 2019" provides an overview of Hepatitis ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on